Low expression of PP2A regulatory subunit B55α is associated with T308 phosphorylation of AKT and shorter complete remission duration in acute myeloid leukemia patients

Leukemia

Volumn 25, Issue 11, 2011, Pages 1711-1717

  Ruvolo, P P ^a   Qui, Y H ^a   Coombes, K R ^a   Zhang, N ^a   Ruvolo, V R ^a   Borthakur, G ^a   Konopleva, M ^a   Andreeff, M ^a   Kornblau, S M ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

AKT; AML; B55 ; PP2A

Indexed keywords

CD34 ANTIBODY; PHOSPHOPROTEIN PHOSPHATASE 2A; PROTEIN KINASE B; THREONINE;

ACUTE GRANULOCYTIC LEUKEMIA; ARTICLE; BLAST CELL; HUMAN; LEUKEMIA REMISSION; MAJOR CLINICAL STUDY; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION;

GENE EXPRESSION PROFILING; HUMANS; LEUKEMIA, MYELOID, ACUTE; PHOSPHORYLATION; PROTEIN PHOSPHATASE 2; PROTO-ONCOGENE PROTEINS C-AKT; REMISSION INDUCTION;

EID: 80755153598     PISSN: 08876924     EISSN: 14765551     Source Type: Journal    
DOI: 10.1038/leu.2011.146     Document Type: Article

References (31)

1. Martelli AM, Evangelisti C, Chiarini F, McCubrey JA. The phosphatidylinositol 3-kinase/Akt/mTOR signaling network as a therapeutic target in acute myelogenous leukemia patients. Oncotarget 2010; 1: 89-103.
2. Fathi AT, Grant S, Karp JE. Exploiting cellular pathways to develop new treatment strategies for AML. Cancer Treat Rev 2010; 36: 142-150.
3. Samudio I, Konopleva M, Carter B, Andreeff M. Apoptosis in leukemias: regulation and therapeutic targeting. Cancer Treat Res 2010; 145: 197-217.
4. Martelli AM, Evangelisti C, Chiarini F, Grimaldi C, Manzoli L, McCubrey JA. Targeting the PI3K/AKT/mTOR signaling network in acute myelogenous leukemia. Expert Opin Investig Drugs 2009; 18: 1333-1349.
5. Martelli AM, Nya°kern M, Tabellini G, Bortul R, Tazzari PL, Evangelisti C et al. Phosphoinositide 3-kinase/Akt signaling pathway and its therapeutical implications for human acute myeloid leukemia. Leukemia 2006; 20: 911-928. (Pubitemid 43797279)
6. Scholl C, Gilliland DG, Fröhling S. Deregulation of signaling pathways in acute myeloid leukemia. Semin Oncol 2008; 35: 336-345.
7. Kornblau SM, Tibes R, Qiu YH, Chen W, Kantarjian HM, Andreeff M et al. Functional proteomic profiling of AML predicts response and survival. Blood 2009; 113: 154-164.
8. Kornblau SM, Womble M, Qiu YH, Jackson CE, Chen W, Konopleva M et al. Simultaneous activation of multiple signal transduction pathways confers poor prognosis in acute myelogenous leukemia. Blood 2006; 108: 2358-2365. (Pubitemid 44497520)
9. Gallay N, Dos Santos C, Cuzin L, Bousquet M, Simmonet Gouy V, Chaussade C et al. The level of AKT phosphorylation on threonine but not on serine 473 is associated with high-risk cytogenetics and predicts poor overall survival in acute myeloid leukaemia. Leukemia 2009; 23: 1029-1038.
10. Hunter T. Protein kinases and phosphatases: the yin and yang of protein phosphorylation and signaling. Cell 1995; 80: 225-236.
11. Millward TA, Zolnierowicz S, Hemmings BA. Regulation of protein kinase cascades by protein phosphatase 2A. Trends Biochem Sci 1999; 24: 186-191. (Pubitemid 29348452)
12. Liao Y, Hung MC. Physiological regulation of Akt activity and stability. Am J Transl Res 2010; 2: 19-42.
13. Kuo YC, Huang KY, Yang CH, Yang YS, Lee WY, Chiang CW. Regulation of phosphorylation of Thr-308 of Akt, cell proliferation, and survival by the B55alpha regulatory subunit targeting of the protein phosphatase 2A holoenzyme to Akt. J Biol Chem 2008; 283: 1882-1892.
14. Chen W, Possemato R, Campbell KT, Plattner CA, Pallas DC, Hahn WC. Identification of specific PP2A complexes involved in human cell transformation. Cancer Cell 2004; 5: 127-136. (Pubitemid 38283799)
15. Chen W, Arroyo JD, Timmons JC, Possemato R, Hahn WC. Cancer-associated PP2A Aalpha subunits induce functional haploinsufficiency and tumorigenicity. Cancer Res 2005; 65: 8183-8192. (Pubitemid 41330582)
16. McCright B, Virshup DM. Identification of a new family of protein phosphatase 2A regulatory subunits. J Biol Chem 1995; 270: 26123-26128.
17. Janssens V, Longin S, Goris J. PP2A holoenzyme assembly: in cauda venenum (the sting is in the tail). Trends Biochem Sci 2008; 33: 113-121.
18. Strack S, Cribbs JT, Gomez L. Critical role for protein phosphatase 2A heterotrimers in mammalian cell survival. J Biol Chem 2004; 279: 47732-47739. (Pubitemid 39540921)
19. Eichhorn PJ, Creyghton MP, Bernards R. Protein phosphatase 2A regulatory subunits and cancer. Biochim Biophys Acta 2009; 1795: 1-15.
20. Sontag E, Nunbhakdi-Craig V, Bloom GS, Mumby MC. A novel pool of protein phosphatase 2A is associated with microtubules and is regulated during the cell cycle. J Cell Biol 1995; 128: 1131-1144.
21. McCright B, Rivers AM, Audlin S, Virshup DM. The B56 family of protein phosphatase 2A (PP2A) regulatory subunits encodes differentiation-induced phosphoproteins that target PP2A to both nucleus and cytoplasm. J Biol Chem 1996; 271: 22081-22089. (Pubitemid 26303837)
22. Ruvolo PP, Clark W, Mumby M, Gao F, May WS. A functional role for the B56 alpha subunit of protein phosphatase 2A in ceramidemediated regulation of Bcl2 phosphorylation status and function. J Biol Chem 2002; 277: 22847-22852. (Pubitemid 34967266)
23. Kornblau SM, Singh N, Qiu Y, Chen W, Zhang N, Coombes KR. Highly phosphorylated FOXO3A is an adverse prognostic factor in acute myeloid leukemia. Clin Cancer Res 2010; 16: 1865-1874.
24. Hu J, He X, Baggerly KA, Coombes KR, Hennessy BT, Mills GB. Non-parametric quantification of protein lysate arrays. Bioinformatics 2007; 23: 1986-1994. (Pubitemid 47299840)
25. Neeley ES, Kornblau SM, Coombes KR, Baggerly KA. Variable slope normalization of reverse phase protein arrays. Bioinformatics 2009; 25: 1384-1389.
26. Li X, Scuderi A, Letsou A, Virshup DM. B56-associated protein phosphatase 2A is required for survival and protects from apoptosis in Drosophila melanogaster. Mol Cell Biol 2002; 22: 3674-3684. (Pubitemid 34525211)
27. Perrotti D, Neviani P. Protein phosphatase 2A (PP2A), a drugable tumor suppressor in Ph1(+) leukemias. Cancer Metastasis Rev 2008; 27: 159-168.
28. Neviani P, Santhanam R, Trotta R, Notari M, Blaser BW, Liu S et al. The tumor suppressor PP2A is functionally inactivated in blast crisis CML through the inhibitory activity of the BCR/ABLregulated SET protein. Cancer Cell 2005; 8: 355-368. (Pubitemid 41579831)
29. Cristóbal I, Blanco FJ, Garcia-Orti L, Marcotegui N, Vicente C, Rifon J et al. SETBP1 overexpression is a novel leukemogenic mechanism that predicts adverse outcome in elderly patients with acute myeloid leukemia. Blood 2010; 115: 615-625.
30. Thimmaiah KN, Easton JB, Houghton PJ. Protection from rapamycin-induced apoptosis by insulin-like growth factor-I is partially dependent on protein kinase C signaling. Cancer Res 2010; 70: 2000-2009.
31. Basu S, Ray NT, Atkinson SJ, Broxmeyer HE. Protein phosphatase 2A plays an important role in stromal cell-derived factor-1/CXC chemokine ligand 12-mediated migration and adhesion of CD34+ cells. J Immunol 2007; 179: 3075-3085.